{"log_id": 15608235092314323, "direction": 0, "words_result_num": 30, "words_result": [{"probability": {"variance": 0.00121, "average": 0.987004, "min": 0.862841}, "location": {"width": 234, "top": 289, "height": 23, "left": 217}, "words": "1.使用理想(偏瘦)体重计算"}, {"probability": {"variance": 0.006108, "average": 0.974312, "min": 0.525023}, "location": {"width": 823, "top": 310, "height": 30, "left": 217}, "words": "2.一般每周一次(假定每周3次血液透析、每次大約持续4小时)。富马酸替诺福韦二吡呋酯应当在完成透析后"}, {"probability": {"variance": 1.3e-05, "average": 0.996392, "min": 0.9928}, "location": {"width": 39, "top": 342, "height": 21, "left": 248}, "words": "给药"}, {"probability": {"variance": 7.8e-05, "average": 0.997242, "min": 0.944094}, "location": {"width": 803, "top": 404, "height": 36, "left": 218}, "words": "在肌酐清除率<10mL分钟的非血液透析患者中,尚未对替诺福韦的药代动力学进行"}, {"probability": {"variance": 1.2e-05, "average": 0.998216, "min": 0.985668}, "location": {"width": 351, "top": 439, "height": 29, "left": 218}, "words": "评价,所以对这些患者没有给药建议"}, {"probability": {"variance": 0.00017, "average": 0.994831, "min": 0.946477}, "location": {"width": 374, "top": 488, "height": 32, "left": 217}, "words": "尚无肾功能损害儿童患者给药建议数据"}, {"probability": {"variance": 0, "average": 0.999801, "min": 0.999685}, "location": {"width": 94, "top": 541, "height": 27, "left": 223}, "words": "不良反应"}, {"probability": {"variance": 3.6e-05, "average": 0.998208, "min": 0.96963}, "location": {"width": 528, "top": 589, "height": 29, "left": 261}, "words": "说明书中的其它小节中,也对以下不良反应进行了讨论"}, {"probability": {"variance": 0.019743, "average": 0.948651, "min": 0.452863}, "location": {"width": 725, "top": 628, "height": 51, "left": 304}, "words": "乳酸酸中毒伴有脂肪变性的重度肝肿大。(参见注意事项)"}, {"probability": {"variance": 0.010141, "average": 0.956416, "min": 0.644971}, "location": {"width": 359, "top": 693, "height": 29, "left": 306}, "words": "中断治疗后乙肝恶化(参见[注意事项])"}, {"probability": {"variance": 0.001361, "average": 0.986888, "min": 0.874836}, "location": {"width": 398, "top": 744, "height": 28, "left": 307}, "words": "新发作或恶化的肾损害。(参见[注意事项"}, {"probability": {"variance": 0.000118, "average": 0.996255, "min": 0.954768}, "location": {"width": 359, "top": 795, "height": 28, "left": 309}, "words": "骨矿物质密度下降。(参见注意事项"}, {"probability": {"variance": 0.000688, "average": 0.983961, "min": 0.938546}, "location": {"width": 133, "top": 696, "height": 132, "left": 940}, "words": "务专用章"}, {"probability": {"variance": 0.003744, "average": 0.980575, "min": 0.738851}, "location": {"width": 340, "top": 846, "height": 29, "left": 308}, "words": "免疫重建综合征。(参见[注意事项)"}, {"probability": {"variance": 0.008239, "average": 0.959144, "min": 0.638607}, "location": {"width": 290, "top": 925, "height": 28, "left": 222}, "words": "成人HIV-1感染患者临床试验"}, {"probability": {"variance": 0.002539, "average": 0.983143, "min": 0.780236}, "location": {"width": 815, "top": 971, "height": 34, "left": 220}, "words": "临床试验:在为期28天~215周的临床试验和记名供药计划中,有12,000多名受试"}, {"probability": {"variance": 0.000102, "average": 0.996705, "min": 0.939117}, "location": {"width": 810, "top": 1001, "height": 30, "left": 222}, "words": "者接受了富马酸替诺福韦二吡呋酯单独治疗或与其他抗逆转录病毒药品联合治疗。在"}, {"probability": {"variance": 0.00353, "average": 0.982695, "min": 0.647408}, "location": {"width": 816, "top": 1030, "height": 29, "left": 221}, "words": "临床试验中,总共有1,44名受试者接受了富马酸替诺福韦二吡呋酯300mg每天一次"}, {"probability": {"variance": 0.00322, "average": 0.984207, "min": 0.653127}, "location": {"width": 821, "top": 1057, "height": 34, "left": 221}, "words": "的治疗:在记名供药计划中有11,000多名受试者接受了富马酸替诺福韦二吡呋酯治疗"}, {"probability": {"variance": 8e-06, "average": 0.998464, "min": 0.984565}, "location": {"width": 797, "top": 1107, "height": 29, "left": 226}, "words": "在这三大对照临床试验中发现最常见不良反应(发生率大于或等于10%,2~4级)"}, {"probability": {"variance": 5e-06, "average": 0.999161, "min": 0.989142}, "location": {"width": 480, "top": 1138, "height": 28, "left": 226}, "words": "包括皮疹、腹泻、头痛、疼痛、抑郁、衰弱和恶心"}, {"probability": {"variance": 1e-06, "average": 0.999054, "min": 0.99717}, "location": {"width": 199, "top": 1189, "height": 26, "left": 225}, "words": "未接受过治疗的患者"}, {"probability": {"variance": 0.006737, "average": 0.985407, "min": 0.479638}, "location": {"width": 808, "top": 1232, "height": 37, "left": 224}, "words": "研究903-治疗引发的不良反应:在600名未接受过治疗的受试者中进行了双盲对照"}, {"probability": {"variance": 5.7e-05, "average": 0.996531, "min": 0.955266}, "location": {"width": 760, "top": 1262, "height": 34, "left": 226}, "words": "试验,患者接受了为期144周的富马酸替诺福韦二吡呋酯(N=299)或司他夫定"}, {"probability": {"variance": 3.2e-05, "average": 0.997423, "min": 0.966861}, "location": {"width": 783, "top": 1289, "height": 36, "left": 243}, "words": "N=301)与拉米夫定和依非韦伦联合治疗(研究903),其中最常见的不良反应为"}, {"probability": {"variance": 5e-06, "average": 0.998696, "min": 0.991191}, "location": {"width": 285, "top": 1324, "height": 26, "left": 225}, "words": "轻至中度的胃肠道事件和头晕"}, {"probability": {"variance": 7e-06, "average": 0.998117, "min": 0.991119}, "location": {"width": 804, "top": 1366, "height": 38, "left": 225}, "words": "轻度不良反应(1级)很常见,两组的发生率相似,包括头晕、腹泻和恶心。经筛选"}, {"probability": {"variance": 2e-06, "average": 0.999018, "min": 0.995875}, "location": {"width": 465, "top": 1399, "height": 32, "left": 226}, "words": "的治疗期间出现的中至重度不良反应总结见表2"}, {"probability": {"variance": 0, "average": 0.801008, "min": 0.801008}, "location": {"width": 49, "top": 1382, "height": 45, "left": 1081}, "words": "上"}, {"probability": {"variance": 0, "average": 0.700703, "min": 0.700703}, "location": {"width": 39, "top": 1426, "height": 38, "left": 1060}, "words": "它"}], "language": 3}